The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

摘要: In the last 3-5 years strong evidence has been gathered demonstrating ErbB3 as a key node for progression of several cancer types. From mechanistic standpoint intracellular region this receptor is rich tyrosine residues that, upon phosphorylation, become high affinity binding sites PI3K and other proteins involved in signal transduction. The involvement occurs at different levels, most likely consequence its promiscuity interaction with RTKs same or families. Several efforts are therefore being put development antibodies that target either singly combination synergizing receptors. Some these compounds have already entered clinical development. Although proof-of-concept not yet achieved, to occur soon will further accelerate inclusion anti-ErbB3 monoclonals repertoire anticancer agents more effective therapy. paper we review wealth under compare their properties potential marketed drugs.